Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Zacks News
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
by Zacks Equity Research
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.
Stryker (SYK) Completes MOLLI's Acquisition to Boost Business
by Zacks Equity Research
Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.
CooperCompanies (COO) Acquires obp Surgical to Boost Portfolio
by Zacks Equity Research
CooperSurgical, a unit of CooperCompanies (COO), acquires obp Surgical for $100 million, adding innovative single-use surgical retractors and suction devices to its portfolio.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
by Zacks Equity Research
Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system.
Inspire Medical (INSP) Gets FDA Nod for Inspire V System
by Zacks Equity Research
Inspire Medical (INSP) secures FDA approval for its advanced Inspire V therapy system, featuring an innovative neurostimulator and Bluetooth technology for enhanced patient and physician control.
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
by Zacks Equity Research
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ecolab (ECL) Sells Surgical Solutions Business to Medline
by Zacks Equity Research
Ecolab's (ECL) deal to sell its global surgical solutions business to Medline enables it to focus on infection prevention and instrument reprocessing while enhancing shareholders' returns.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.
Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook
by Zacks Equity Research
Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
by Mark Vickery
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts
by Zacks Equity Research
Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
by Zacks Equity Research
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash
by Zacks Equity Research
QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.
Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.
4 Stocks to Watch From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.